Guangzhou InnoCare Named 2026 Guangdong Advanced Smart Factory
Guangzhou InnoCare Pharma Technology Co. , Ltd. has been recognized as a 2026 Guangdong Advanced Smart Factory for its integrated intelligent manufacturing platform for innovative drug R&D and production. The facility has established a full-scenario digital system covering R&D, production, and operations, enabling closed-loop digital control across production environments, processes, materials, and safety. Its operations integrate intelligent systems to connect equipment and software, merging virtual and physical systems. The platform, which meets multiple GMP standards, features advanced spray-drying and hot-melt extrusion lines and three drug delivery technology platforms to address poorly soluble drug challenges.
Guangzhou InnoCare Pharma Technology Co. , Ltd. was recently named a '2026 Guangdong Advanced Smart Factory'. The recognition was granted for the company's achievements in building an 'integrated intelligent factory for innovative drug R&D and production'.
Guangzhou InnoCare has established a full-scenario digital system covering R&D, production, and operations. On the production and management side, multiple intelligent systems enable closed-loop digital control over the entire process, including production environment, process operations, material warehousing, and safety. On the operations management side, it integrates multiple intelligent system management tools, connecting intelligent equipment and software systems, and merging virtual and physical systems to achieve integrated R&D and production of innovative drugs.
With the integration of these systems, Guangzhou InnoCare has built an efficient and collaborative intelligent operations system. In production operations, multi-system linkage enables closed-loop management of the entire production chain, with real-time collection of energy consumption data and intelligent energy allocation, balancing stable production with energy conservation. In quality and safety management, the coordinated operation of multiple systems ensures full-process traceability and control of quality and safety.
As InnoCare's core platform for the industrialization of proprietary innovative drugs, Guangzhou InnoCare has built intelligent production facilities that meet multiple GMP standards of China, Europe, and the United States, connecting the complete chain from drug molecule R&D to large-scale manufacturing. The platform features internationally advanced spray-drying and hot-melt extrusion solid dispersion and solid dosage form production lines, and has established three technology platforms: solubilization of poorly soluble drugs, oral solid dosage form modified-release, and targeted delivery, to address the dissolution challenges of poorly soluble drugs.